Blog Layout

Sequence analysis of mutations and translocations across breast cancer subtypes

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone1. This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy2, 3, 4. Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notablyERBB2 amplifications, the first successful therapy target defined by a genomic aberration5. Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements6, 7, 8, 9, 10. Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA11, TP536, AKT112, GATA313 and MAP3K110, we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3–AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3–AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.



Share this Article with others

By Sorena Nadaf February 13, 2025
January 2025 Newsletter: The Year of Artificial Intelligence Sorena Nadaf-Rahrov, MS, MMI, PhDc
By Sorena Nadaf February 5, 2025
A recent Lancet study demonstrated that AI implementation led to a 29% increase in cancer detection, with no increase in false positives and a reduced workload compared to radiologists without AI assistance. While emerging evidence supports AI’s potential to enhance cancer detection in mammography screening and reduce screen-reading workload, further research is needed to fully understand its clinical impact.
By Sorena Nadaf December 10, 2024
Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
By Sorena Nadaf November 11, 2024
With heavy hearts, we remember and honor Brady Davis, whose sudden passing leaves an immense void. Brady was a devoted supporter and invaluable contributor to the Cancer Center Informatics Society, dedicating countless hours to advancing our mission and strengthening our community. His expertise, enthusiasm, and unwavering commitment shaped our initiatives and inspired everyone fortunate enough to work alongside him. Brady’s legacy will live on through the progress he championed and the connections he fostered. We extend our deepest sympathies to his family, friends, and all who knew him. He will be greatly missed. In honor of Brady’s legacy, Ci4CC will be forming a committee to explore meaningful ways to memorialize him within our society for years to come. We plan to announce the committee’s recommendations at our Spring Summit in San Diego, CA, on March 31, 2025. Please find his obituary here , and visit his memorial page on MyKeeper to leave a tribute. Support the Davis family in Brady’s memory via GoFundMe ---------- Cancer Center Informatics Society (Ci4CC) Sorena Nadaf-Rahrov & Warren Kibbe Co-Founders, Ci4CC
By Sorena Nadaf October 29, 2024
Nature Digital Medicine PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models
By Sorena Nadaf September 4, 2024
American Cancer Society and Color Health to Provide Free At-Home Colorectal Cancer Screening in Underserved Rural Communities
September 4, 2024
Leading Progress Against Cancer
August 24, 2024
By Drs Karen Knudsen & Othman Laraki.
By Sorena Nadaf July 18, 2024
Conversation with The Cancer Letter: NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready” - July 12, 2024
By Sorena Nadaf July 11, 2024
"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019" American Cancer Society
Share by: